Jennifer Kielmeyer, GSW, recently attended the second DTxDM conference of the year, which was held on Sept. 25-26 in Boston, MA. The conference brought together more than 200 senior decision-makers from digital therapeutics companies, pharma, investors, payers, and healthcare providers—nearly double the attendance of the same conference in San Francisco just six months prior.
As the growing attendee count infers, growth in this space is significant. With that growth often comes more questions than answers as many seek to get a solid understanding of the best path forward for their emerging businesses. Here are some of the questions that stood out as the most important that remain to be answered for the industry.
This content was repurposed from PM360.
